Navigation Links
Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease

an improvement in cognitive domains often impaired in these patients, in particular executive function (the ability for planning, organizing, strategizing and paying attention to and remembering details) and working memory.
Treatment with safinamide at a dose of 50 to 100 mg once daily over a 24-week period resulted in a statistically significant improvement in tests assessing executive function, such as the Strategic Target Detection Test2 (STDT), compared with dopamine agonist monotherapy. A statistically significant improvement was also observed in tests for working memory such as Auditory Number Sequencing3 (ANS). Tests assessing manual dexterity and attention/vigilance were not statistically different across treatment groups.
From baseline to the 24th week, cognitive data were available for 41 patients randomized to safinamide 50 to 100 mg once daily, 38 to safinamide 150 to 200 mg once daily and 44 to placebo. Cognitive effects were seen as early as 12 weeks after starting safinamide treatment. The higher safinamide dose range of 150 to 200 mg per day did not offer any incremental advantage over safinamide 50 to 100 mg per day dose range based on STDT and ANS.
The side effects observed in the safinamide group were similar to those observed in the placebo group. The most frequent side effects were gastro-intestinal disorders (nausea, vomiting, abdominal pain upper).

The cognitive effects of safinamide will be further investigated in other clinical trials.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and restless leg syndrome, as per the agreement signed with Newron in October 2006.
1 Phase III data presented at American Academy of Neurology 59th Annual Meeting in Boston, Massachusetts, USA:
The data are from a trial conducted in Europe, South America and Asia. A total of 2
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
8. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
9. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
10. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
11. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
Post Your Comments:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According ... on medical technology market intelligence, the ... and occlusion (TEO) device markets will expand moderately ... the fastest-growing segments. In particular, increasing interest in ... oncology has fueled rapid growth of these markets. ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ... fat content and preserved lean body mass following ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... stove instead of the traditional indoor open fire, experienced improved ... habit, according to a recent study. The study, ... project examining the impact of the use of vented stoves ... 1 issue of the American Journal of Respiratory and ...
... ... up with Zogby International to poll voters in competitive House and Senate 2010 elections ... may want to proceed with extreme caution on health care. , ... (PRWEB) September 22, 2009 -- Recently ...
... , , RADNOR, Pa., Sept. 22 The ... Topaz Kessler Meltzer & Check, LLP: , , ... in the United States District Court for the Eastern District of ... BLUD ) ("Immucor" or the "Company") between October 19, ...
... , , FLINT, Mich., Sept. 22 ... closer to receiving one of the most advanced forms of treatment ... and ProTom International, a Texas-based health care technology company. , ... Radiance 330 , combines the most ...
... SOUTHAMPTON, Pa., Sept. 22 Environmental Tectonics Corporation,s ... Systems today announced the sale of an additional BARA-MED((R)) ... , , Comprehensive Healthcare Solutions is ... operating wound healing institutes throughout the United States. This ...
... , , , Two ... , , Sixty-eight percent do not want ... , Sixty-three percent favor keeping conscience protection laws , ... the United States Conference of Catholic Bishops (USCCB) has found widespread public opposition ...
Cached Medicine News:Health News:New stove dramatically improves lung health in Mexican women 2Health News:New stove dramatically improves lung health in Mexican women 3Health News:Brad O'Leary: New Poll: Health Care Issues Loom Large for 2010 Elections 2Health News:Brad O'Leary: New Poll: Health Care Issues Loom Large for 2010 Elections 3Health News:Shareholder Class Action Filed Against Immucor, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 2Health News:Shareholder Class Action Filed Against Immucor, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 3Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 2Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 3Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 4Health News:Environmental Tectonics Corporation Places a BARA-MED(R) XD Monoplace Hyperbaric Chamber with Comprehensive Healthcare Solutions, Inc. 2Health News:Environmental Tectonics Corporation Places a BARA-MED(R) XD Monoplace Hyperbaric Chamber with Comprehensive Healthcare Solutions, Inc. 3Health News:Environmental Tectonics Corporation Places a BARA-MED(R) XD Monoplace Hyperbaric Chamber with Comprehensive Healthcare Solutions, Inc. 4Health News:New Survey: Most Americans Want Health Care Reform, Oppose Abortion Coverage, Support Conscience Protection Laws 2
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... TowerPack is an innovative, quick ... Diamond Tips. Use 60% less space ... less plastic. With this amazingly easy-to-use, ... box for the whole range of ...
... use: when presented in convenient, steady, ... to pick up directly from the ... 96 tips are loaded without manual ... a security sticker. Fully autoclavable, Tipacks ...
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
Medicine Products: